Myriad Genetics Inc

NASDAQ:MYGNUnited States

Today

Show headlines and story abstract

• DJ Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight, from 5 hours ago by Dow Jones

  5 hours ago by Dow Jones
  Companies Mentioned: MYGN
  
  By Sabela Ojea
  
  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
  

• Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction, from 5 hours ago by MT Newswires

  5 hours ago by MT Newswires
  Companies Mentioned: MYGN
  10:56 AM EST, 11/04/2024 (MT Newswires) -- Myriad Genetics (MYGN) said Monday that it "strongly disagrees" with UnitedHealthcare's decision to restrict coverage access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, und...

• Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing, from 8 hours ago by Dow Jones

  8 hours ago by Dow Jones
  Companies Mentioned: MYGN
  
  Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing
  
  SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1(st) , 2025.